NASDAQ$EOLS
Evolus Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Evolus Inc reported Q2 2025 results with total revenue of $69.4 million and a net loss of $17.1 million.
Evolus launched Evolysse Form and Smooth in the United States during the quarter, generating $9.7 million in revenue. Total net revenues increased 3.7% year-over-year to $69.4 million, driven by the new product launch offsetting a decline in Jeuveau sales amid softer toxin demand. The company reported a net loss of $17.1 million and ended the quarter with $61.7 million in cash and cash equivalents.
- Evolysse contributed $9.7 million in its first quarter of U.S. sales following the April 2025 launch.
- Jeuveau revenue declined to $59.0 million from $66.2 million in Q2 2024 due to macroeconomic pressures on consumer demand.
- Gross profit margin compressed to 65.3% from 70.3% year-over-year due to product mix shift toward Evolysse.
- Net loss widened to $17.1 million as operating expenses rose with commercial and training investments for the new product line.
Headline financials
Revenue & EPS history
Evolus · Revenue · Quarterly
$69.4M
Revenue by segment
Evolus · $68.7M total across 2 segments · Q2 2025
- Jeuveau$59M—85.8%
- Evolysse$9.73M—14.2%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+0.5%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+35.4%
Q4 2025
Best reaction
-26.9%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +4.7% | +19.3% | — | |
| Q4 2025 | +35.4% | +29.5% | -2.4% | |
| Q3 2025 | +5.4% | +2.6% | +0.6% | |
| Q1 2025 | -14.2% | -13.9% | -14.6% | |
| Q4 2024 | -1.3% | -11.6% | -25.5% | |
| Q3 2024 | -13.3% | -20.4% | -23.2% | |
| Q2 2024 | +15.2% | +9.2% | +30.4% | |
| Q1 2024 | -1.0% | -4.8% | -7.4% | |
| Q4 2023 | -0.3% | -0.1% | -6.0% | |
| Q3 2023 | +9.7% | +0.4% | +20.3% | |
| Q2 2023 | -1.2% | -8.3% | -2.6% | |
| Q1 2023 | +17.8% | +14.9% | -3.9% | |
| Q4 2022 | -6.4% | -7.7% | -8.5% | |
| Q3 2022 | -8.4% | -3.2% | -1.6% | |
| Q2 2022 | -26.9% | -28.3% | -30.3% | |
| Q1 2022 | +9.2% | +29.0% | +20.4% | |
| Q4 2021 | +1.8% | +3.0% | +25.0% | |
| Q3 2021 | -9.5% | -10.0% | -33.3% | |
| Q2 2021 | -6.9% | +1.7% | -15.1% | |
| Q1 2021 | -0.9% | +2.4% | +41.1% | |
| Q4 2020 | -21.1% | -28.2% | -43.0% | |
| Q3 2020 | -1.9% | +2.3% | +23.9% | |
| Q2 2020 | +6.6% | +6.0% | +2.6% | |
| Q1 2020 | +4.8% | -9.7% | +32.9% | |
| Q4 2019 | -3.4% | -8.1% | -51.9% | |
| Q3 2019 | -2.2% | -10.7% | -20.3% | |
| Q2 2019 | -10.9% | -21.8% | -6.7% | |
| Q1 2019 | -7.5% | -5.1% | -46.4% | |
| Q4 2018 | +7.0% | -3.3% | -2.7% | |
| Q3 2018 | -5.8% | -6.6% | -10.6% | |
| Q2 2018 | +6.0% | +8.2% | +34.8% | |
| Q1 2018 | +27.9% | +38.9% | +142.4% | |
| Q4 2017 | +8.5% | +9.1% | -15.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro